20-F: Mainz Biomed N.V. Files Form 20-F, Details ColoAlert Expansion and U.S. Market Entry Strategy

Mainz Biomed N.V. files its annual report on Form 20-F, outlining its business strategy, financial performance, and risk factors, with a focus on expanding its ColoAlert product in Europe and entering the U.S. market.

Summary

• Mainz Biomed N.V., a Dutch company focused on early cancer detection, filed its annual report on Form 20-F for the fiscal year ended December 31, 2023.
• The company's flagship product, ColoAlert, is being marketed in Europe, and the company is developing a next-generation colorectal cancer screening test for launch in the U.S. and Europe.
• The company incurred net losses of approximately $26.3 million in both 2023 and 2022.
• Revenue for 2023 was $895,479, a 69% increase compared to $529,877 in 2022, driven by increased ColoAlert sales.
• Research and development expenses increased to $9.6 million in 2023 from $5.0 million in 2022, primarily due to increased headcount and clinical study costs.
• The company is pursuing FDA market authorization for ColoAlert in the U.S. and plans to initiate a pivotal study.
• The company acknowledges substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.
• The company intends to fund its operations through current cash, future debt, and equity financings.
• The company faces competition from colonoscopies, FIT tests, and other companies developing novel CRC screening tests.
• The company's strategy includes collaborations with large laboratory chains for distribution and a decentralized product and marketing approach in the U.S.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue is growing and there's progress in clinical studies, the company is still operating at a loss and faces significant risks, including going concern uncertainty. The sentiment is neutral, reflecting both positive developments and serious challenges.

Positives

• Revenue increased by 69% in 2023, indicating growing market acceptance of ColoAlert.
• Gross profit margins increased from 34% to 57% due to higher margin sales in the diagnostic lab.
• The company is actively pursuing FDA approval for ColoAlert in the U.S., opening a significant market opportunity.
• The company has a strategic focus on collaborations with large laboratory chains for distribution.
• The company has a strong research and development team and is supported by government grants.
• The company announced topline results from its eAArly DETECT U.S. clinical study which reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%.

Negatives

• The company has incurred significant operating losses since inception and expects to continue to incur losses in the future.
• The company's auditor has expressed substantial doubt about the company's ability to continue as a going concern.
• The company's future success depends heavily on the commercial success of ColoAlert.
• The company faces competition from established CRC screening methods and other companies developing novel tests.
• The company may face difficulties protecting its intellectual property.
• The company may depend on possible future collaborations to develop and commercialize many of our diagnostic test candidates and to provide the manufacturing, regulatory compliance, sales, marketing and distribution capabilities required for the success of our business.

Risks

• The company may not be successful in preventing the material adverse effects that any of the risks and uncertainties may cause.
• The company may not be successful in generating sufficient revenue from its relationships with its clients or laboratory partners to achieve and maintain profitability.
• Sales of the company's diagnostic tests could be adversely impacted by the reluctance of physicians to adopt the use of the company's tests and by the availability of competing diagnostic tests.
• The company might decide not to incorporate the UdeS Biomarkers after it concludes additional studies on such biomarkers.
• If third party payors do not provide reimbursement, breach, rescind or modify their contracts or reimbursement policies or delay payments for the company's tests, or the company is unable to successfully renegotiate reimbursement contracts, the company's commercial success could be compromised.
• The company may depend on possible future collaborations to develop and commercialize many of its diagnostic test candidates and to provide the manufacturing, regulatory compliance, sales, marketing and distribution capabilities required for the success of its business.
• Results of FDA required studies may not create desired clinical performance resulting in follow-on studies delaying the launch of the product in the US.
• The market price of the company's ordinary shares may be volatile and may fluctuate in a way that is disproportionate to the company's operating performance.
• You may experience dilution of your ownership interests if the company issues additional ordinary shares or preferred shares.
• If the company is, or were to become, a passive foreign investment company (a PFIC) for U.S. federal income tax purposes, U.S. investors in the company's ordinary shares would be subject to certain adverse U.S. federal income tax consequences.

Future Outlook

The company plans to expand the commercial opportunity of ColoAlert in Europe, prepare for FDA market authorization in the U.S., and continue research and development of PancAlert.

Industry Context

The company operates in the cancer diagnostics segment, competing with traditional CRC screening methods like colonoscopies and FIT tests, as well as other companies developing novel CRC screening tests.

Comparison to Industry Standards

• The company competes with Exact Sciences (Cologuard), Freenome Holdings, Geneoscopy Inc., Guardant Health, Inc., GRAIL, Inc., and Universal DX.
• Exact Sciences Cologuard boasts a sensitivity of 92% and specificity of 87%, with an average reimbursement rate of $500, as reported in a New England Journal of Medicine study.
• Freenome Holdings is pioneering a blood-based CRC screening test that employs a multimodal data approach, with pivotal FDA study results and clearance anticipated in the next 12 months.
• Geneoscopys stool RNA test ColoSense has shown promising sensitivity and specificity rates in detecting CRC and advanced adenomas during clinical trials, with an FDA decision on pre-marketing approval expected in 2024.
• Guardant Healths Shield blood test detects colorectal cancer signals, including circulating tumor DNA, with high sensitivity and specificity, as demonstrated in clinical validation studies, and are also targeting a commercial launch of the product in the US sometime in 2024.
• GRAILs Galleri blood test can detect over 50 types of cancer, intended for use alongside traditional screening methods, priced at $959.
• Universal DX is developing Signal-C, a liquid biopsy screening test for CRC, currently undergoing validation to demonstrate sensitivity and specificity metrics, with FDA approval in process.

Related Party Transactions

• The company has entered into various silent partnership (loan) agreements with different investors.
• During the year ended December 31, 2023, the repayment of EUR150,000 (approximately $161,010) of the 8.5% SPAs was a related party transaction, who is a major shareholder.
• As at December 31, 2023, EUR 200,000 (approximately $220,784) with a carrying value of $271,354 of the 8.5% SPAs were owing to major shareholders of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial condition and need for additional funding.
• Employees face uncertainty due to the company's going concern risk and potential need to curtail operations.
• Customers may be impacted by the company's ability to continue providing and developing diagnostic tests.
• Suppliers and creditors face the risk of non-payment due to the company's financial condition.

Next Steps

• Expand the commercial opportunity of ColoAlert in Europe.
• Prepare and execute a comprehensive clinical and regulatory strategy to achieve market authorization from the FDA to use ColoAlert as a screening test for CRC in the United States.
• Continue research and development of PancAlert.

Key Dates

Keywords

ColoAlert, colorectal cancer, screening, diagnostic tests, FDA, IVD, Mainz Biomed, PancAlert, biomarkers, PCR